Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Hypertension. 2019 Dec 23;75(2):569–579. doi: 10.1161/HYPERTENSIONAHA.119.14056

Figure 4. Transcriptional regulation of RGS2 by the cAMP/CREB signaling pathway is impaired in human PreE.

Figure 4.

(A) Dose- and time-dependent responses of RGS2 mRNA in HTR8/SVneo cells treated with Forskolin (n=3 each dose / time), and serine-133 phosphorylated CREB (pCREB) presence at the RGS2 promoter in HTR8 cells after treatment with FSK (n=7 each). (B) cAMP concentrations (Control n=8, PreE n=11), ratio of serine-133 phosphorylated CREB to total CREB (Control n=4, PreE n=5), and serine-133 phosphorylated CREB presence at the RGS2 promoter (Control n=7, PreE n=6) in placenta from humans with or without PreE. (C) Correlation of RGS2 mRNA content to pCREB occupancy at the RGS2 promoter in human placental tissue (Control n=5, PreE n=6); comparison of curves by extra sum-of-squares: F=56.65 (2,7), p<0.0001. (D) NR4A1, NR4A3, CREM, and RGS2 mRNA in HTR8/SVneo cells after stimulation by forskolin in the presence or absence of the non-selective HDAC inhibitor, SAHA (Vehicle n=11, SAHA n=14). (E) Serine-133 phosphorylated CREB occupancy at the RGS2 and FOS promoters of HTR8/SVneo cells (n=4 each). (F) Canonical CREB target gene expression in human placentas by in silico reanalysis of GSE75010 (Control n=22, PreE n=47). Summary data presented as mean±SEM. *p<0.05 by t-test (A, B, F) or Tukey multiple-comparison procedure (D, E).